Ratifi Español Sign in
Ratifi

Federal bills from Congress.gov. State bills from Open States.

A 3125Session 222

What changed between versions

69 paragraphs changed+473 words added−781 removed

Highlighted text was added in the newer version. Struck-through text was removed.

LEGISLATIVE FISCAL ESTIMATE

[First Reprint]

ASSEMBLY, No. 3125

STATE OF NEW JERSEY

222nd LEGISLATURE

DATED: FEBRUARY 23, 2026

SUMMARY

Synopsis:

PRE-FILED FOR INTRODUCTION IN THE 2026 SESSION

Sponsored by:

Assemblywoman LISA SWAIN

District 38 (Bergen)

Assemblywoman SHAMA A. HAIDER

District 37 (Bergen)

Assemblywoman SHANIQUE SPEIGHT

District 29 (Essex and Hudson)

Co-Sponsored by:

Assemblyman Sampson, Assemblywomen McCoy, Flynn, Pintor Marin, Assemblyman Miller, Assemblywomen Park, Brennan, Murphy, Assemblyman Bhalla, Assemblywoman Drulis, Assemblyman Freiman, Assemblywomen Rowan, Morales and Sweeney

SYNOPSIS

Limits perfluoroalkyl and polyfluoroalkyl substances in menstrual products.

Type of Impact:

Annual State expenditure and revenue increases.

Agencies Affected:

Department of Law and Public Safety; Department of Environmental Protection; Department of Health.

Office of Legislative Services Estimate

Annual Fiscal Impact

State Expenditure Increase

Indeterminate

State Revenue Increase

Indeterminate

· The Office of Legislative Services (OLS) determines that the bill would result in indeterminate annual State expenditure and revenue increases.

· The Department of Environmental Protection would incur one-time expenditures to establish a system for manufacturers to periodically test for the presence of perfluoroalkyl or polyfluoroalkyl substances in various menstrual products.

· The Department of Health would incur ongoing costs to the extent the department requests to inspect the results of tests performed under the bill.

· The Department of Law and Public Safety would incur ongoing costs for enforcement activities to the extent there are violations of the bill’s provisions.

· The OLS anticipates an increase in State revenues from unlawful practices penalties of up to $10,000 for a first offense and up to $20,000 for any subsequent offense. However, the OLS has no information on which to base an estimate of the number and magnitude of future penalty assessments and payments and thus cannot project the amount the State will collect.

BILL DESCRIPTION

CURRENT VERSION OF TEXT

As reported by the Assembly Consumer Affairs Committee on February 12, 2026, with amendments.

TheAn billAct limits the use oflimiting perfluoroalkyl and polyfluoroalkyl (PFAS) substances in menstrual products and supplementing P.L.1960, c.39 (C.56:8-1 et seq.).

products.

Be It Enacted by the Senate and General Assembly of the State of New Jersey:

1. a. As used in this act:

The1 bill prohibits "intentionally“Intentionally added PFAS,"” defined by the bill asmeans PFAS added to a product or onea of the product'sproduct’s components to provide a specific characteristic, appearance, or quality or to perform a specific function. andThe term includes any degradation byproducts of PFAS, orbut the presence of PFAS in a product or product component at or aboveexcludes a technically unavoidable trace quantity, of PFAS as measured in total organic fluorine. 1

“Menstrual product” means a product manufactured for the purpose of catching menstruation and vaginal discharge, including but not limited to a tampon, sanitary pad, disc, menstrual cup, and underwear. The term shall include both disposable and reusable products.

“Perfluoroalkyl and polyfluoroalkyl substances” or “PFAS” means the same as defined in subsection k. of section 1 of P.L.2023, c.243 (C.56:8-229).

1 [ “Regulated perfluoroalkyl and polyfluoroalkyl substances” or “Regulated PFAS” means:

(1) "Intentionally added PFAS," which means PFAS added to a product or one of the product's components to provide a specific characteristic, appearance, or quality or to perform a specific function and includes any degradation byproducts of PFAS; or

(2) the presence of PFAS in a product or product component at or above a technically unavoidable trace quantity, as measured in total organic fluorine. ] 1

b. A manufacturer of menstrual products shall not sell, distribute, or offer for sale or use in this State any menstrual product containing 1 [ regulated ] intentionally added 1 PFAS.

c. (1) The bill requires the Department of Environmental Protection toshall establish a system for manufacturers to periodically test for the presence of 1 [ regulated ] intentionally added 1 PFAS andin approvemenstrual of laboratories to conduct the tests. Results of any test conducted pursuant to the bill are requiredproducts, to be availableconducted toby a laboratory approved by the Department of Health for inspection, either from the manufacturer or the laboratorycommissioner.

(2) The billcommissioner also requires the Department of Environmental Protection toshall publish on itsthe department’s Internet website a list of approved laboratories and a list of acceptable testing methods to be used to satisfy the requirements of paragraph (1) of this subsection.

A violation of the bill’s provisions would be an unlawful practice under the Consumer Fraud Act, P.L.1960, c.39. The bill would be effective two years after enactment; however, the bill permits the Department of Environmental Protection and the Department of Health to take anticipatory administrative action.

FISCAL ANALYSIS

EXECUTIVE BRANCH

None received.

OFFICE OF LEGISLATIVE SERVICES

The OLS determines that the bill would result in indeterminate annual State expenditure and revenue increases.

The Department of Environmental Protection would incur one-time expenditures to establish a system for manufacturers to periodically test for the presence of perfluoroalkyl or polyfluoroalkyl substances in various menstrual products.

The Department of Health would incur ongoing costs to the extent the department requests to inspect the results of tests performed under the bill.

The Department of Law and Public Safety would incur ongoing costs for enforcement activities to the extent there are violations of the bill’s provisions. The bill establishes that a violation of the bill’s provisions would be an unlawful practice under the Consumer Fraud Act and would be punishable by a monetary penalty of not more than $10,000 for a first offense and not more than $20,000 for any subsequent offense. Additionally, a violation of the Consumer Fraud Act can result in cease and desist orders issued by the Attorney General, the assessment of punitive damages, and the awarding of treble damages and costs to the injured. The OLS anticipates an increase in State revenues from unlawful practices penalties; however, the OLS has no information on which to base an estimate of the number and magnitude of future penalty assessments and payments and thus cannot project the amount the State will collect.

In 2019, New York became the first state in the nation to require manufacturers of menstrual products to disclose ingredients. Shortly after, California and Nevada joined in the requirement. From November 2021 to February 2022, the non-profit organization Women’s Voices for the Earth conducted a field study examining ingredient disclosures on period product labels both in New York and across the United States. The May 2022 report issued by the organization examined the findings of that field study, notably indicating that the compliance with the law to disclose ingredients had not been perfect. A few products evaluated in the field study did not disclose ingredients at all, or more frequently, only provided vague descriptions of ingredients disclosed without the actual chemical names of ingredients being included.

Section:

Law and Public Safety

Analyst:

Kristin Brunner Santos

Lead Fiscal Analyst

Approved:

Thomas Koenig

Legislative Budget and Finance Officer

This legislative fiscal estimate has been produced by the Office of Legislative Services due to the failure of the Executive Branch to respond to our request for a fiscal note.

This fiscal estimate has been prepared pursuant to P.L.1980, c.67 (C.52:13B-6 et seq.).

d. The results of a test conducted pursuant to subsection c. of this section shall be available to the Department of Health for inspection upon request to the manufacturer or laboratory.

e. A violation of the provisions of this section shall constitute an unlawful practice for the purposes of P.L.1960, c.39 (C.56:8-1 et seq.), and the violator shall be subject to all the remedies and penalties available pursuant to P.L.1960, c.39 (C.56:8-1 et seq.).

2. This act shall take effect on the first day of the 25th month next following enactment, except that the Commissioner of Environmental Protection and the Commissioner of Health may take any anticipatory administrative action in advance as may be necessary for the implementation of this act.

Back to the full text